董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ron Mayron | 男 | Chairman of the Board | 61 | 未披露 | 未持股 | 2026-05-17 |
| Yonatan Malca | 男 | Director | 59 | 未披露 | 未持股 | 2026-05-17 |
| Eyal Shamir | 男 | Chief Executive Officer and Director | 65 | 84.60万美元 | 未持股 | 2026-05-17 |
| Yang Huang | 男 | Director | 46 | 未披露 | 未持股 | 2026-05-17 |
| Vincent Chun Hung Chan | 男 | Director | 61 | 未披露 | 未持股 | 2026-05-17 |
| Sharon Levita | 女 | Director | 57 | 未披露 | 未持股 | 2026-05-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eyal Shamir | 男 | Chief Executive Officer and Director | 65 | 84.60万美元 | 未持股 | 2026-05-17 |
| Shay Levav | 男 | Chief Operating Officer | 49 | 36.10万美元 | 未持股 | 2026-05-17 |
| Tlalit Bussi Tel Tzure | 女 | Vice President, Business Development and Global Marketing | 53 | 37.70万美元 | 未持股 | 2026-05-17 |
| Meir Peleg | 男 | Chief Financial Officer | 50 | 未披露 | 未持股 | 2026-05-17 |
| Merav Nir Dotan | 女 | Vice President, Human Resources | 56 | 未披露 | 未持股 | 2026-05-17 |
| Shad Good | 男 | Vice President, Sales for North America | 48 | 41.50万美元 | 未持股 | 2026-05-17 |
| Meir Peleg | 男 | Chief Financial Officer | -- | 未披露 | 未持股 | 2026-05-17 |
董事简历
中英对照 | 中文 | 英文- Ron Mayron
-
Ron Mayron，他也曾任职Icecure Medical Ltd.的董事会，担任独立董事（2011年4月以来），也是Icecure Medical Ltd.的审计、薪酬、财务报表、公司治理和投资委员会的成员。他担任ADY Consulting Group的战略和业务顾问。任职ADY Consulting Group之前，他曾担任Netafim公司的联席首席执行官。此前，他曾担任Teva公司的多种高级职务20年以上，包括高级商业开发副总裁、首席信息官、中欧和东欧副总裁。他持有Bar Ilan University的经济学学士学位。
Ron Mayron has served as Chairman of board of directors since December 2017. Mr. Mayron has served as chairman of the board of directors of Resymmetry Ltd. from July 2016 to January 2022, InnoCan Pharma Corporation (CSE: INNO, FWB: IP4, OTC: INNPF) from November 2017 to October 2025, Virility Medical LTD from October 2019 to March 2023 and as a member of the board of directors of G Med Ltd. since September 2015, Kaizen Bio Tec Ltd. since May 2017, Simplivia Ltd. from May 2019 to January 2026, Matricelf LTD (TASE MTLF.TA) Chairman of the board since October 2025, Kadimastem LTD (TASE: KDST) from December 2020 to December 2023, Entera Bio Ltd. (NASDAQ: ENTX) from March 2021 to July 2024 and DNA Biomedical Solutions (TASE: DNA) from March 2021 to May 2023, Ir Med, Inc. (OTC:IRME) since March 2021, NureXone (CDNX) from December 2021 to July 2023. Mr. Mayron has also served as the founder and chief executive officer of RonMed Ltd. Prior to that, Mr. Mayron served as a member of the board of directors of EclipeIR (A) Inc. from June 2016 to September 2019 and BioLight Life Sciences Investments Ltd. (TASE: BOLT) from Augt 2015 to July 2024. Mr. Mayron also served in vario positions at Teva Pharmaceutical Indtries Ltd. (NYSE: TEVA, TASE: TEVA) from 1993 to 2014, including as vice president–Israel and Africa and chief executive officer of Teva Israel from 2009 to 2013. Mr. Mayron received his B.Sc. in indtrial and management engineering from Ben Gurion University of the Negev, Israel and MBA from Tel Aviv University, Israel. Mr. Mayron also completed a special senior management and global leadership programs at the Massachetts Institute of Technology (M.I.T), Boston and managerial skills for international biness and executive international marketing programs at Insead University, France. - Ron Mayron，他也曾任职Icecure Medical Ltd.的董事会，担任独立董事（2011年4月以来），也是Icecure Medical Ltd.的审计、薪酬、财务报表、公司治理和投资委员会的成员。他担任ADY Consulting Group的战略和业务顾问。任职ADY Consulting Group之前，他曾担任Netafim公司的联席首席执行官。此前，他曾担任Teva公司的多种高级职务20年以上，包括高级商业开发副总裁、首席信息官、中欧和东欧副总裁。他持有Bar Ilan University的经济学学士学位。
- Ron Mayron has served as Chairman of board of directors since December 2017. Mr. Mayron has served as chairman of the board of directors of Resymmetry Ltd. from July 2016 to January 2022, InnoCan Pharma Corporation (CSE: INNO, FWB: IP4, OTC: INNPF) from November 2017 to October 2025, Virility Medical LTD from October 2019 to March 2023 and as a member of the board of directors of G Med Ltd. since September 2015, Kaizen Bio Tec Ltd. since May 2017, Simplivia Ltd. from May 2019 to January 2026, Matricelf LTD (TASE MTLF.TA) Chairman of the board since October 2025, Kadimastem LTD (TASE: KDST) from December 2020 to December 2023, Entera Bio Ltd. (NASDAQ: ENTX) from March 2021 to July 2024 and DNA Biomedical Solutions (TASE: DNA) from March 2021 to May 2023, Ir Med, Inc. (OTC:IRME) since March 2021, NureXone (CDNX) from December 2021 to July 2023. Mr. Mayron has also served as the founder and chief executive officer of RonMed Ltd. Prior to that, Mr. Mayron served as a member of the board of directors of EclipeIR (A) Inc. from June 2016 to September 2019 and BioLight Life Sciences Investments Ltd. (TASE: BOLT) from Augt 2015 to July 2024. Mr. Mayron also served in vario positions at Teva Pharmaceutical Indtries Ltd. (NYSE: TEVA, TASE: TEVA) from 1993 to 2014, including as vice president–Israel and Africa and chief executive officer of Teva Israel from 2009 to 2013. Mr. Mayron received his B.Sc. in indtrial and management engineering from Ben Gurion University of the Negev, Israel and MBA from Tel Aviv University, Israel. Mr. Mayron also completed a special senior management and global leadership programs at the Massachetts Institute of Technology (M.I.T), Boston and managerial skills for international biness and executive international marketing programs at Insead University, France.
- Yonatan Malca
-
Yonatan Malca自2011年以来一直担任我们的董事会成员。他目前担任D.N.A Biomedical公司的首席执行官兼董事（2010年以来）。Malca先生还担任Arko Holdings Ltd.的董事。TASE:Arko，NextGen-BioMed Ltd.TASE:NXGN和Tamda Ltd.（TASE:TMDA），均为以色列上市公司。Malca先生还任职于多家私人公司的董事会，包括担任医疗器械公司CardioArt Technologies Ltd.和医疗器械公司Beamed Ltd.（D.N.A Biomedical的子公司）的董事会主席。Malca先生拥有以色列巴伊兰大学（Bar-Ilan University）的经济学和统计学学士学位以及巴伊兰大学（Bar Ilan University）的经济学和金融学硕士学位。
Yonatan Malca has served as a member of Entera Bio Ltd. Board since 2011. Mr. Malca currently serves as Chief Executive Officer and a director of NanoGohst Ltd. From 2009 to 2021, he served as Chief Executive Officer and a director of DNA Biomedical Solutions Ltd. (TASE: DNA). Mr. Malca also serves as a director of Jungo Connectivity Ltd. (TASE: JNGO) and Unicorn Technologies (TASE: UNCT), both Israeli public companies. He also serves as director of BeamMed Ltd, a private medical device company. He previously served as a director of Nextgen Biomed LTD. (TASE: NXGN) from July 2018 to April 2019, ARKO Holdings Ltd. from August 2014 to December 2020, and Tamda Ltd. from July 2016 to September 2020. Mr. Malca holds a B.A. in Economics and Statistics from Bar Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel. - Yonatan Malca自2011年以来一直担任我们的董事会成员。他目前担任D.N.A Biomedical公司的首席执行官兼董事（2010年以来）。Malca先生还担任Arko Holdings Ltd.的董事。TASE:Arko，NextGen-BioMed Ltd.TASE:NXGN和Tamda Ltd.（TASE:TMDA），均为以色列上市公司。Malca先生还任职于多家私人公司的董事会，包括担任医疗器械公司CardioArt Technologies Ltd.和医疗器械公司Beamed Ltd.（D.N.A Biomedical的子公司）的董事会主席。Malca先生拥有以色列巴伊兰大学（Bar-Ilan University）的经济学和统计学学士学位以及巴伊兰大学（Bar Ilan University）的经济学和金融学硕士学位。
- Yonatan Malca has served as a member of Entera Bio Ltd. Board since 2011. Mr. Malca currently serves as Chief Executive Officer and a director of NanoGohst Ltd. From 2009 to 2021, he served as Chief Executive Officer and a director of DNA Biomedical Solutions Ltd. (TASE: DNA). Mr. Malca also serves as a director of Jungo Connectivity Ltd. (TASE: JNGO) and Unicorn Technologies (TASE: UNCT), both Israeli public companies. He also serves as director of BeamMed Ltd, a private medical device company. He previously served as a director of Nextgen Biomed LTD. (TASE: NXGN) from July 2018 to April 2019, ARKO Holdings Ltd. from August 2014 to December 2020, and Tamda Ltd. from July 2016 to September 2020. Mr. Malca holds a B.A. in Economics and Statistics from Bar Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel.
- Eyal Shamir
-
Eyal Shamir自2016年9月起担任我们的首席执行官，自2017年12月起担任董事会成员。Shamir先生拥有超过15年的医疗设备公司首席执行官的经验。他曾担任Erika Carmel Ltd.（2013年5月至2016年8月）、Tadbik Pack Ltd.（2011年1月至2012年12月）和Hanita Lens Ltd.（2006年至2010年）的首席执行官。Shamir先生在以色列希伯来大学获得经济学和商业管理学士学位，在以色列管理学院获得工商管理硕士学位。
Eyal Shamir has served as Chief Executive Officer since September 2016 and on board of directors since December 2017. Mr. Shamir has over 20 years of experience as chief executive officer of medical device companies. He has served as chief executive officer of Erika Carmel Ltd. from May 2013 to Augt 2016, Tadbik Pack Ltd. from January 2011 to December 2012 and Hanita Lenses Ltd. from 2006 to 2010. Mr. Shamir received his B.A. in economics and biness management from the Hebrew University, Israel and his MBA from the College of Management Academic Studies, Israel. - Eyal Shamir自2016年9月起担任我们的首席执行官，自2017年12月起担任董事会成员。Shamir先生拥有超过15年的医疗设备公司首席执行官的经验。他曾担任Erika Carmel Ltd.（2013年5月至2016年8月）、Tadbik Pack Ltd.（2011年1月至2012年12月）和Hanita Lens Ltd.（2006年至2010年）的首席执行官。Shamir先生在以色列希伯来大学获得经济学和商业管理学士学位，在以色列管理学院获得工商管理硕士学位。
- Eyal Shamir has served as Chief Executive Officer since September 2016 and on board of directors since December 2017. Mr. Shamir has over 20 years of experience as chief executive officer of medical device companies. He has served as chief executive officer of Erika Carmel Ltd. from May 2013 to Augt 2016, Tadbik Pack Ltd. from January 2011 to December 2012 and Hanita Lenses Ltd. from 2006 to 2010. Mr. Shamir received his B.A. in economics and biness management from the Hebrew University, Israel and his MBA from the College of Management Academic Studies, Israel.
- Yang Huang
-
Yang Huang自2020年4月以来一直在我们的董事会任职。Huang先生在医疗器械领域拥有20年的高级销售与市场营销管理经验。黄先生自2019年7月起还担任私募股权基金Virtus Inspire Ventures的运营董事，自2020年7月起担任Icecure Shanghai Medtech Co.，Ltd.的企业代表，此前，黄先生于2016年11月至2019年7月担任奥林巴斯（北京）销售服务有限公司业务单元总监，并于2015年1月至2016年11月担任B.Braun医疗（上海）国际贸易有限公司业务单元总监。黄先生毕业于中国长江商学院和中国浙江医科大学。
Yang Huang has served on board of directors since April 2020. Mr. Huang has 20 years of senior sales and marketing management experience in the field of medical devices. Mr. Huang has also served as operation directors of Virt Inspire Ventures, a private equity fund, since July 2019 and as a corporate representative of IceCure (Shanghai) MedTech Co., Ltd. since July 2020, Prior to that, Mr. Huang has served as biness unit director of Olymp (Beijing) Sales & Service Co., Ltd. from November 2016 to July 2019 and as biness unit director of B. Braun MEDICAL (SHANGHAI) International Trading Co., Ltd. from January 2015 to November 2016. He also served as biness unit head for Stryker from September 2013 through January 2015 and as sales manager at Johnson & Johnson from October 2000 through Augt 2013. Mr. Huang has graduated from Cheung Kong Graduate School of Biness, China and Zhejiang Medical University, China. - Yang Huang自2020年4月以来一直在我们的董事会任职。Huang先生在医疗器械领域拥有20年的高级销售与市场营销管理经验。黄先生自2019年7月起还担任私募股权基金Virtus Inspire Ventures的运营董事，自2020年7月起担任Icecure Shanghai Medtech Co.，Ltd.的企业代表，此前，黄先生于2016年11月至2019年7月担任奥林巴斯（北京）销售服务有限公司业务单元总监，并于2015年1月至2016年11月担任B.Braun医疗（上海）国际贸易有限公司业务单元总监。黄先生毕业于中国长江商学院和中国浙江医科大学。
- Yang Huang has served on board of directors since April 2020. Mr. Huang has 20 years of senior sales and marketing management experience in the field of medical devices. Mr. Huang has also served as operation directors of Virt Inspire Ventures, a private equity fund, since July 2019 and as a corporate representative of IceCure (Shanghai) MedTech Co., Ltd. since July 2020, Prior to that, Mr. Huang has served as biness unit director of Olymp (Beijing) Sales & Service Co., Ltd. from November 2016 to July 2019 and as biness unit director of B. Braun MEDICAL (SHANGHAI) International Trading Co., Ltd. from January 2015 to November 2016. He also served as biness unit head for Stryker from September 2013 through January 2015 and as sales manager at Johnson & Johnson from October 2000 through Augt 2013. Mr. Huang has graduated from Cheung Kong Graduate School of Biness, China and Zhejiang Medical University, China.
- Vincent Chun Hung Chan
-
Vincent Chun Hung Chan自2021年3月起担任Samena Capital董事，主要从事私募股权投资，并于2016年至2021担任Samena Capital高级常务董事兼亚洲区负责人。1991年至2016年，他服务于多家领先的私募股权投资公司，包括HSBC Equity Management Co., Ltd、Suez Asia Holdings Hong Kong Co., Ltd.、JAFCO投资（亚太）有限公司和Spring Capital Asia，Limited。Chan 先生自2020年9月17日起担任China Logistics International Holdings Limited（其股票在香港联合交易所有限公司（“联交所”）（股票代码：2130）主板上市）的独立非执行董事，以及memory Group Co., Ltd. 的非执行董事，其股票在新加坡交易所证券交易有限公司Catalist上市（股票代码：1H4）。Chan先生现任香港风险投资及私人股本协会主席兼执行董事。Chan先生自2020年7月起担任香港联合交易所主板和创业板上市审查委员会成员。他曾于2007年5月至2012年5月担任香港联合交易所主板及创业板上市委员会委员。2005年7月至2011年3月，他还是香港证监会公众股东小组的成员。Chan先生于1986年11月获得香港大学文学士学位，并于1988年7月获得英国曼彻斯特商学院（当时称为曼彻斯特维多利亚大学）工商管理硕士学位。1993年9月，他被美国特许金融分析师协会聘为特许金融分析师。
Vincent Chun Hung Chan has served on board of directors since December 2022. Mr. Chan has been a venture partner at Beyond Ventures since Augt 2024 and was a partner from October 2023 to July 2024. Also, he was a Senior Managing Director and Head of Asia of Samena Capital Hong Kong Limited from 2016 to 2021. From 1991 to 2016, he served several leading private equity investment companies including HSBC Equity Management Limited, Suez Asia Holdings (Hong Kong) Limited, JAFCO Investment (Asia Pacific) Ltd and Spring Capital Asia, Limited. Mr. Chan has been an independent non executive director of CN Logistics International Holdings Limited since September 2020, and an independent non executive director of ITC PROPERTIES GROUP LIMITED since NOVEMBER 2025. Mr. Chan is currently the Director and Treasurer of the Hong Kong Venture Capital and Private Equity Association, and a non executive director of the Hong Kong securities and futures commission. Mr. Chan WAS a member of the Main Board and GEM Listing Review Committees of the Stock Exchange of Hong Kong from 2020 to 2024. He was previoly a member of the Main Board and GEM Listing Committee of the Stock Exchange of Hong Kong from May 2007 to May 2012. He was also a member of the Public Shareholders Group of the Hong Kong Securities and Futures Commission from July 2005 to March 2011. Mr. Chan received a Bachelor of Arts degree from the University of Hong Kong in November 1986 and a master's degree in biness administration from the Manchester Biness School (then known as the Victoria University of Manchester) in the United Kingdom in July 1988. He was admitted as a chartered financial analyst of the Institute of Chartered Financial Analysts, United States in September 1993. - Vincent Chun Hung Chan自2021年3月起担任Samena Capital董事，主要从事私募股权投资，并于2016年至2021担任Samena Capital高级常务董事兼亚洲区负责人。1991年至2016年，他服务于多家领先的私募股权投资公司，包括HSBC Equity Management Co., Ltd、Suez Asia Holdings Hong Kong Co., Ltd.、JAFCO投资（亚太）有限公司和Spring Capital Asia，Limited。Chan 先生自2020年9月17日起担任China Logistics International Holdings Limited（其股票在香港联合交易所有限公司（“联交所”）（股票代码：2130）主板上市）的独立非执行董事，以及memory Group Co., Ltd. 的非执行董事，其股票在新加坡交易所证券交易有限公司Catalist上市（股票代码：1H4）。Chan先生现任香港风险投资及私人股本协会主席兼执行董事。Chan先生自2020年7月起担任香港联合交易所主板和创业板上市审查委员会成员。他曾于2007年5月至2012年5月担任香港联合交易所主板及创业板上市委员会委员。2005年7月至2011年3月，他还是香港证监会公众股东小组的成员。Chan先生于1986年11月获得香港大学文学士学位，并于1988年7月获得英国曼彻斯特商学院（当时称为曼彻斯特维多利亚大学）工商管理硕士学位。1993年9月，他被美国特许金融分析师协会聘为特许金融分析师。
- Vincent Chun Hung Chan has served on board of directors since December 2022. Mr. Chan has been a venture partner at Beyond Ventures since Augt 2024 and was a partner from October 2023 to July 2024. Also, he was a Senior Managing Director and Head of Asia of Samena Capital Hong Kong Limited from 2016 to 2021. From 1991 to 2016, he served several leading private equity investment companies including HSBC Equity Management Limited, Suez Asia Holdings (Hong Kong) Limited, JAFCO Investment (Asia Pacific) Ltd and Spring Capital Asia, Limited. Mr. Chan has been an independent non executive director of CN Logistics International Holdings Limited since September 2020, and an independent non executive director of ITC PROPERTIES GROUP LIMITED since NOVEMBER 2025. Mr. Chan is currently the Director and Treasurer of the Hong Kong Venture Capital and Private Equity Association, and a non executive director of the Hong Kong securities and futures commission. Mr. Chan WAS a member of the Main Board and GEM Listing Review Committees of the Stock Exchange of Hong Kong from 2020 to 2024. He was previoly a member of the Main Board and GEM Listing Committee of the Stock Exchange of Hong Kong from May 2007 to May 2012. He was also a member of the Public Shareholders Group of the Hong Kong Securities and Futures Commission from July 2005 to March 2011. Mr. Chan received a Bachelor of Arts degree from the University of Hong Kong in November 1986 and a master's degree in biness administration from the Manchester Biness School (then known as the Victoria University of Manchester) in the United Kingdom in July 1988. He was admitted as a chartered financial analyst of the Institute of Chartered Financial Analysts, United States in September 1993.
- Sharon Levita
-
Sharon Levita，从2008年2月起担任公司的首席财务官。在加入Mazor之前，她于1999年至2008年在Lumenis Ltd.（一家医疗激光和光技术公司）担任多种职位，包括业务发展总监、财务执行副总裁和财务总监。她持有Bar-Ilan University的工商管理硕士学位（金融方向），还从Haifa University。获得了经济与会计的学士学位。她还是一名注册会计师。
Sharon Levita has served on board of directors as an external director since September 2019. Ms. Levita has also served as chief financial officer at ForSight Robotics Ltd. since September 2023. Prior to that, Ms. Levita served as biness development and strategy director at Medtronics from February 2020 to Augt 2023, as vice president operations and site leader of Mazor, as part of Medtronic, from December 2018 to January 2020 and as chief financial officer and vice president biness operations of Mazor Robotics Ltd. from February 2008 to December 2018. Ms. Levita received her B.A in economics and accounting from the University of Haifa and her M.A in biness administration from the Bar Ilan University. Ms. Levita is also a certificated public accountant in Israel. - Sharon Levita，从2008年2月起担任公司的首席财务官。在加入Mazor之前，她于1999年至2008年在Lumenis Ltd.（一家医疗激光和光技术公司）担任多种职位，包括业务发展总监、财务执行副总裁和财务总监。她持有Bar-Ilan University的工商管理硕士学位（金融方向），还从Haifa University。获得了经济与会计的学士学位。她还是一名注册会计师。
- Sharon Levita has served on board of directors as an external director since September 2019. Ms. Levita has also served as chief financial officer at ForSight Robotics Ltd. since September 2023. Prior to that, Ms. Levita served as biness development and strategy director at Medtronics from February 2020 to Augt 2023, as vice president operations and site leader of Mazor, as part of Medtronic, from December 2018 to January 2020 and as chief financial officer and vice president biness operations of Mazor Robotics Ltd. from February 2008 to December 2018. Ms. Levita received her B.A in economics and accounting from the University of Haifa and her M.A in biness administration from the Bar Ilan University. Ms. Levita is also a certificated public accountant in Israel.
高管简历
中英对照 | 中文 | 英文- Eyal Shamir
Eyal Shamir自2016年9月起担任我们的首席执行官，自2017年12月起担任董事会成员。Shamir先生拥有超过15年的医疗设备公司首席执行官的经验。他曾担任Erika Carmel Ltd.（2013年5月至2016年8月）、Tadbik Pack Ltd.（2011年1月至2012年12月）和Hanita Lens Ltd.（2006年至2010年）的首席执行官。Shamir先生在以色列希伯来大学获得经济学和商业管理学士学位，在以色列管理学院获得工商管理硕士学位。
Eyal Shamir has served as Chief Executive Officer since September 2016 and on board of directors since December 2017. Mr. Shamir has over 20 years of experience as chief executive officer of medical device companies. He has served as chief executive officer of Erika Carmel Ltd. from May 2013 to Augt 2016, Tadbik Pack Ltd. from January 2011 to December 2012 and Hanita Lenses Ltd. from 2006 to 2010. Mr. Shamir received his B.A. in economics and biness management from the Hebrew University, Israel and his MBA from the College of Management Academic Studies, Israel.- Eyal Shamir自2016年9月起担任我们的首席执行官，自2017年12月起担任董事会成员。Shamir先生拥有超过15年的医疗设备公司首席执行官的经验。他曾担任Erika Carmel Ltd.（2013年5月至2016年8月）、Tadbik Pack Ltd.（2011年1月至2012年12月）和Hanita Lens Ltd.（2006年至2010年）的首席执行官。Shamir先生在以色列希伯来大学获得经济学和商业管理学士学位，在以色列管理学院获得工商管理硕士学位。
- Eyal Shamir has served as Chief Executive Officer since September 2016 and on board of directors since December 2017. Mr. Shamir has over 20 years of experience as chief executive officer of medical device companies. He has served as chief executive officer of Erika Carmel Ltd. from May 2013 to Augt 2016, Tadbik Pack Ltd. from January 2011 to December 2012 and Hanita Lenses Ltd. from 2006 to 2010. Mr. Shamir received his B.A. in economics and biness management from the Hebrew University, Israel and his MBA from the College of Management Academic Studies, Israel.
- Shay Levav
Shay Levav自2020年9月起担任我们的副总裁，负责监管和质量保证以及临床应用。在加入公司之前，Levav先生自2018年12月至2020年9月担任Applied Spectral Imaging的董事会成员，自2015年1月至2018年12月担任其质量和监管事务经理。他还从2012年到2015年担任Carestream Health Inc.的商业化业务经理，从2001年到2012年担任其运营质量经理，从2000年到2001年担任服务工程师。利瓦夫先生拥有以色列鲁宾学院中心的学士学位。
Shay Levav has served as Chief Operating Officer since November 2025 and has previoly served as Vice President, Regulatory and Quality Assurance and Clinical Applications since September 2020. Before joining the Company, Mr. Levav served as a Quality Assurance and Regulatory Affairs director at Applied Spectral Imaging from December 2018 to Augt 2020 and as its quality and regulatory affairs manager since January 2015 to December 2018. He has also served as commercialization biness manager of Carestream Health Inc. from 2012 to 2015, as its operations quality manager from 2001 to 2012, and service engineer since 2000 to 2001. Mr. Levav is a Certified Quality Engineer (CQE) by the American Society of Quality (ASQ).- Shay Levav自2020年9月起担任我们的副总裁，负责监管和质量保证以及临床应用。在加入公司之前，Levav先生自2018年12月至2020年9月担任Applied Spectral Imaging的董事会成员，自2015年1月至2018年12月担任其质量和监管事务经理。他还从2012年到2015年担任Carestream Health Inc.的商业化业务经理，从2001年到2012年担任其运营质量经理，从2000年到2001年担任服务工程师。利瓦夫先生拥有以色列鲁宾学院中心的学士学位。
- Shay Levav has served as Chief Operating Officer since November 2025 and has previoly served as Vice President, Regulatory and Quality Assurance and Clinical Applications since September 2020. Before joining the Company, Mr. Levav served as a Quality Assurance and Regulatory Affairs director at Applied Spectral Imaging from December 2018 to Augt 2020 and as its quality and regulatory affairs manager since January 2015 to December 2018. He has also served as commercialization biness manager of Carestream Health Inc. from 2012 to 2015, as its operations quality manager from 2001 to 2012, and service engineer since 2000 to 2001. Mr. Levav is a Certified Quality Engineer (CQE) by the American Society of Quality (ASQ).
- Tlalit Bussi Tel Tzure
Tlalit Bussi Tel Tzure自2018年12月起担任我们的副总裁，负责业务发展和全球营销。Bussi Tel-Tzure女士拥有超过20年的医疗器械公司的销售、业务开发和营销经验。她曾担任DIA Imaging Analysis Ltd.的营销副总裁（从2017年4月到2018年12月），以及Medical Compression System Ltd.的销售与市场营销的副总裁（从2012年9月到2017年8月）。Bussi Tel-Tzure女士在以色列希伯来大学获得理学学士学位，在英国赫里奥瓦特大学获得工商管理硕士学位。
Tlalit Bussi Tel Tzure has served as Vice President, Biness Development and Global Marketing, since December 2018. Ms. Bsi Tel Tzure has more than 20 years of sales, biness developments and marketing of medical device companies. She has served as vice president of marketing of DiA Imaging Analysis Ltd. form April 2017 to December 2018, and as vice president of sales and marketing of Medical Compression System Ltd. from September 2012 to Augt 2017. Ms. Bsi Tel Tzure received her Bachelor of Science from the Hebrew University, Israel and her MBA from the Heriot Watt University, United Kingdom.- Tlalit Bussi Tel Tzure自2018年12月起担任我们的副总裁，负责业务发展和全球营销。Bussi Tel-Tzure女士拥有超过20年的医疗器械公司的销售、业务开发和营销经验。她曾担任DIA Imaging Analysis Ltd.的营销副总裁（从2017年4月到2018年12月），以及Medical Compression System Ltd.的销售与市场营销的副总裁（从2012年9月到2017年8月）。Bussi Tel-Tzure女士在以色列希伯来大学获得理学学士学位，在英国赫里奥瓦特大学获得工商管理硕士学位。
- Tlalit Bussi Tel Tzure has served as Vice President, Biness Development and Global Marketing, since December 2018. Ms. Bsi Tel Tzure has more than 20 years of sales, biness developments and marketing of medical device companies. She has served as vice president of marketing of DiA Imaging Analysis Ltd. form April 2017 to December 2018, and as vice president of sales and marketing of Medical Compression System Ltd. from September 2012 to Augt 2017. Ms. Bsi Tel Tzure received her Bachelor of Science from the Hebrew University, Israel and her MBA from the Heriot Watt University, United Kingdom.
- Meir Peleg
Meir Peleg，自2017年9月起担任Gauzy Ltd. 首席财务官。在加入Gauzy Ltd.之前，2014年至2017年期间，Peleg先生在F.B.M. Composite Materials Ltd.担任首席财务官，该公司是一家领先的飞机行业复合材料零部件制造商。在此之前，2011年至2014年期间，Peleg先生在TechSign Advanced Signs Systems Ltd.担任首席财务官，该公司是寻路标牌系统（Vista Systems）的开发商和制造商。在此之前，2005年至2011年期间，Peleg先生在全球专业服务、会计和咨询公司普华永道担任主管。Peleg先生拥有经济学和计算机科学理学学士学位、会计学证书、工商管理硕士学位，均来自Bar-Ilan大学。
Meir Peleg,has served as Gauzy Ltd. Chief Financial Officer since September 2017. Prior to joining Gauzy Ltd. , between 2014 and 2017, Mr. Peleg served as Chief Financial Officer at F.B.M. Composite Materials Ltd., a leading composite parts manufacturer for the aircraft industry. Prior to that, between 2011 and 2014, Mr. Peleg served as Chief Financial Officer at Techsign Advanced Signs Systems Ltd., a developer and manufacturer of wayfinding signage systems (Vista Systems). Prior to that, between 2005 and 2011, Mr. Peleg served as a Supervisor at PricewaterhouseCoopers, a global professional services, accounting, and consulting firm. Mr. Peleg holds a Bachelor of Science degree in Economics and Computer Science, an accounting studies certificate, and a Master's degree in Business Administration, all from Bar-Ilan University.- Meir Peleg，自2017年9月起担任Gauzy Ltd. 首席财务官。在加入Gauzy Ltd.之前，2014年至2017年期间，Peleg先生在F.B.M. Composite Materials Ltd.担任首席财务官，该公司是一家领先的飞机行业复合材料零部件制造商。在此之前，2011年至2014年期间，Peleg先生在TechSign Advanced Signs Systems Ltd.担任首席财务官，该公司是寻路标牌系统（Vista Systems）的开发商和制造商。在此之前，2005年至2011年期间，Peleg先生在全球专业服务、会计和咨询公司普华永道担任主管。Peleg先生拥有经济学和计算机科学理学学士学位、会计学证书、工商管理硕士学位，均来自Bar-Ilan大学。
- Meir Peleg,has served as Gauzy Ltd. Chief Financial Officer since September 2017. Prior to joining Gauzy Ltd. , between 2014 and 2017, Mr. Peleg served as Chief Financial Officer at F.B.M. Composite Materials Ltd., a leading composite parts manufacturer for the aircraft industry. Prior to that, between 2011 and 2014, Mr. Peleg served as Chief Financial Officer at Techsign Advanced Signs Systems Ltd., a developer and manufacturer of wayfinding signage systems (Vista Systems). Prior to that, between 2005 and 2011, Mr. Peleg served as a Supervisor at PricewaterhouseCoopers, a global professional services, accounting, and consulting firm. Mr. Peleg holds a Bachelor of Science degree in Economics and Computer Science, an accounting studies certificate, and a Master's degree in Business Administration, all from Bar-Ilan University.
- Merav Nir Dotan
Merav Nir Dotan，自2021年11月起担任人力资源副总裁。Nir Dotan女士在人力资源和组织管理方面拥有超过二十年的经验。Nir Dotan女士曾于2009年至2020年担任Hanita Lenses的人力资源副总裁，该公司是一家医疗设备制造商和白内障手术人工晶状体解决方案提供商。此外，从2020年12月到2022年1月，Nir Dotan女士在咨询和项目管理公司RNR-Sys兼职。Nir Dotan女士拥有特拉维夫大学组织行为学理学硕士学位，并在内盖夫的本-古里安大学获得人力资源本科学位。
Merav Nir Dotan has served as Vice President, Human Resces, since November 2021. Mrs. Nir Dotan has over two decades of experience in human resces and organizational management. Mrs. Nir Dotan was previoly Vice President of Human Resces at Hanita Lenses, a medical device manufacturer and provider of intraocular lens solutions for cataract surgery, from 2009 to 2020. In addition, from December 2020 through January 2022, Mrs. Nir Dotan worked part time for RNR Sys, a consulting and project management company. Mrs. Nir Dotan has a Master of Science in Organizational Behavior from Tel Aviv University and received her undergraduate degree in Human Resces from Ben Gurion University of the Negev.- Merav Nir Dotan，自2021年11月起担任人力资源副总裁。Nir Dotan女士在人力资源和组织管理方面拥有超过二十年的经验。Nir Dotan女士曾于2009年至2020年担任Hanita Lenses的人力资源副总裁，该公司是一家医疗设备制造商和白内障手术人工晶状体解决方案提供商。此外，从2020年12月到2022年1月，Nir Dotan女士在咨询和项目管理公司RNR-Sys兼职。Nir Dotan女士拥有特拉维夫大学组织行为学理学硕士学位，并在内盖夫的本-古里安大学获得人力资源本科学位。
- Merav Nir Dotan has served as Vice President, Human Resces, since November 2021. Mrs. Nir Dotan has over two decades of experience in human resces and organizational management. Mrs. Nir Dotan was previoly Vice President of Human Resces at Hanita Lenses, a medical device manufacturer and provider of intraocular lens solutions for cataract surgery, from 2009 to 2020. In addition, from December 2020 through January 2022, Mrs. Nir Dotan worked part time for RNR Sys, a consulting and project management company. Mrs. Nir Dotan has a Master of Science in Organizational Behavior from Tel Aviv University and received her undergraduate degree in Human Resces from Ben Gurion University of the Negev.
- Shad Good
Shad Good，自2023年9月19日起担任北美销售副总裁。在加入公司之前，Good先生于2022年4月至2023年8月担任UV-Concepts Inc的销售副总裁。2017年7月至2022年3月，Good先生在丹纳赫公司的运营公司Mammotome担任美国地区高级销售总监，在那里他领导了该公司乳腺微创活检系统的销售工作，并为成功推出一项新兴技术——一种用于肿块切除的无线设备——建立了一个销售组织。古德先生拥有俄亥俄州迈阿密大学市场营销学士学位。
Shad Good has served as Vice President, Sales for North America since September 19, 2023. Before joining the Company, Mr. Good was VP of Sales at UV Concepts Inc from April 2022 to Augt 2023. From July 2017 to March 2022, Mr. Good was Senior Director of Sales, U.S., at Mammotome, an operating company of Danaher Corporation, where he led sales for the company's minimally invasive breast biopsy systems and built a sales organization for the successful launch of an emerging technology, a wire free device for lumpectomies. Mr. Good holds a B.S. in Marketing from Miami University of Ohio.- Shad Good，自2023年9月19日起担任北美销售副总裁。在加入公司之前，Good先生于2022年4月至2023年8月担任UV-Concepts Inc的销售副总裁。2017年7月至2022年3月，Good先生在丹纳赫公司的运营公司Mammotome担任美国地区高级销售总监，在那里他领导了该公司乳腺微创活检系统的销售工作，并为成功推出一项新兴技术——一种用于肿块切除的无线设备——建立了一个销售组织。古德先生拥有俄亥俄州迈阿密大学市场营销学士学位。
- Shad Good has served as Vice President, Sales for North America since September 19, 2023. Before joining the Company, Mr. Good was VP of Sales at UV Concepts Inc from April 2022 to Augt 2023. From July 2017 to March 2022, Mr. Good was Senior Director of Sales, U.S., at Mammotome, an operating company of Danaher Corporation, where he led sales for the company's minimally invasive breast biopsy systems and built a sales organization for the successful launch of an emerging technology, a wire free device for lumpectomies. Mr. Good holds a B.S. in Marketing from Miami University of Ohio.
- Meir Peleg
Meir Peleg是一位经验丰富的上市公司CFO，拥有深厚的资本市场经验，独特地将软件工程背景与20多年的财务领导相结合。他在领导成功的纳斯达克 IPO和多次大规模融资方面有着良好的业绩记录，同时将全球工业技术组织从早期成长阶段扩展到全球700多名员工。Peleg先生为并购和上市公司治理带来了数据驱动的系统方法，此前曾担任CEO和董事会的战略合作伙伴，以实现股东价值最大化并推动企业长期增长。他是以色列的注册会计师，拥有BAR-Ilan大学的MBA和经济学和计算机科学学士学位。
Meir Peleg,is a seasoned public company CFO with deep capital markets experience, uniquely combining a software engineering background with over 20 years of financial leadership. He has a proven track record leading a successful Nasdaq IPO and multiple large-scale capital raises, while scaling global industrial-tech organizations from early growth stages to 700+ employees worldwide. Mr. Peleg brings a data-driven, systematic approach to M&A, and public company governance, having previously served as a strategic partner to CEOs and boards in maximizing shareholder value and driving long-term enterprise growth. He is a Certified Public Accountant in Israel and holds an MBA and a BA in Economics and Computer Science from Bar-Ilan University.- Meir Peleg是一位经验丰富的上市公司CFO，拥有深厚的资本市场经验，独特地将软件工程背景与20多年的财务领导相结合。他在领导成功的纳斯达克 IPO和多次大规模融资方面有着良好的业绩记录，同时将全球工业技术组织从早期成长阶段扩展到全球700多名员工。Peleg先生为并购和上市公司治理带来了数据驱动的系统方法，此前曾担任CEO和董事会的战略合作伙伴，以实现股东价值最大化并推动企业长期增长。他是以色列的注册会计师，拥有BAR-Ilan大学的MBA和经济学和计算机科学学士学位。
- Meir Peleg,is a seasoned public company CFO with deep capital markets experience, uniquely combining a software engineering background with over 20 years of financial leadership. He has a proven track record leading a successful Nasdaq IPO and multiple large-scale capital raises, while scaling global industrial-tech organizations from early growth stages to 700+ employees worldwide. Mr. Peleg brings a data-driven, systematic approach to M&A, and public company governance, having previously served as a strategic partner to CEOs and boards in maximizing shareholder value and driving long-term enterprise growth. He is a Certified Public Accountant in Israel and holds an MBA and a BA in Economics and Computer Science from Bar-Ilan University.